A5077389546- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Neutropenia and Cancer Infections
- Acute Lymphoblastic Leukemia research
- Renal Transplantation Outcomes and Treatments
- T-cell and B-cell Immunology
- Cytomegalovirus and herpesvirus research
- Multiple Myeloma Research and Treatments
- Polyomavirus and related diseases
- Chronic Myeloid Leukemia Treatments
- Immune Cell Function and Interaction
- Chronic Lymphocytic Leukemia Research
- Inflammatory Bowel Disease
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Mycobacterium research and diagnosis
- CAR-T cell therapy research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Immunotherapy and Immune Responses
- COVID-19 Clinical Research Studies
- Viral-associated cancers and disorders
- COVID-19 and healthcare impacts
- Multiple Sclerosis Research Studies
- Pneumocystis jirovecii pneumonia detection and treatment
- Antifungal resistance and susceptibility
Hospital Universitari de Vic
2025
Universitat de Barcelona
2013-2025
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2015-2025
Hospital Clínic de Barcelona
2015-2024
Josep Carreras Leukaemia Research Institute
2012-2024
Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer
2023-2024
Fundación Josep Carreras Contra la Leucemia
2018-2024
University of Padua
2022
National Marrow Donor Program
2015
Spanish Society of Hematology and Hemotherapy
2009-2011
The evolution of the incidence, morbidity, and mortality veno-occlusive disease (VOD) was analyzed in 845 allogeneic hematopoietic stem cell transplantations (allo-HSCTs) performed over 24 years. A total 117 patients 73 developed VOD following Seattle Baltimore diagnostic criteria, respectively (cumulative incidence 13.8% 8.8%). cumulative significantly higher period 1985 to 1996 than 1997 2008 (11.5% vs 6.5%; P = .01). This decline because low among reduced-intensity conditioning-HSCT...
We evaluated the occurrence of severe infections in 192 consecutive adult recipients volunteer unrelated donor allogeneic hematopoietic stem cell transplants, with a detailed analysis after receipt cord blood transplants (CBTs; n = 48) or bone marrow (BMTs)/peripheral (PBSCTs; 144). At 3-year median follow-up, CBT had higher risk developing any infection (85% versus 69% BMT/PBSCT recipients, P < .01). incidence bacterial before day +100, but at 3 years risks these and other were similar...
There is endothelial activation and damage in hematopoietic stem cell transplantation (HSCT). The impact of the conditioning type HSCT on dysfunction early phases has been evaluated. Plasma samples were obtained before at different times after autologous allogeneic with without complications. Changes soluble markers (VWF, ADAMTS-13, sVCAM-1, sICAM-1, sTNFRI) measured. changes all evaluated that followed patterns auto allo settings. For VWF sTNRI, progressive increases from day Pre to 14 21...
Haematopoietic stem cell transplantation [HSCT] is considered a therapeutic option for patients with severe Crohn's disease [CD] unresponsive to currently available therapies. Autologous HSCT was CD active disease, or intolerant approved medications and unsuitable surgery. After HSCT, were closely followed up every 6 weeks during the first 2 years months thereafter 5 years. Colonoscopy and/or magnetic resonance imaging performed at Months 6, 12, 24, 48 after HSCT. From December 1, 2007 31,...
<h3>Objective</h3> To evaluate the feasibility and toxicity of autologous haematopoietic stem cell transplantation (HSCT) for treatment refractory Crohn9s disease (CD). <h3>Design</h3> In this prospective study, patients with CD suffering an aggressive course despite medical treatment, impaired quality life in whom surgery was not acceptable option underwent HSCT. Toxicity complications during procedure within first year following were evaluated, along impact introduction supportive measures...
Summary European LeukemiaNet refined their risk classification of acute myeloid leukaemia (AML) in 2022 (ELN 2022) according to the two new classifications published same year. We have retrospectively assessed prognostic value ELN 120 AML patients undergoing allogeneic haematopoietic cell transplantation (allo‐HCT), including 99 first complete response (CR1) from 2011 2021 our centre. Adverse (Adv) presented inferior outcome terms overall survival (OS) and leukaemia‐free (LFS) (OS [ p =...
This study evaluated the relative impact of intensity conditioning regimen and alloreactivity in endothelial dysfunction occurring after allogeneic hematopoietic stem cell transplantation (allo-HSCT). It involved a comparative analysis effect incubating human umbilical vein cells (ECs) with serum samples from patients receiving autologous HSCT (auto-HSCT) or unrelated donor allo-HSCT. In both groups, blood were collected through central line before (Pre), (day 0), at days 7, 14, 21...
The optimal prophylaxis regimen for graft-versus-host disease (GVHD) in the setting of mismatched unrelated donor (MMUD) allogeneic hematopoietic stem cell transplantation (alloHSCT) is not defined. use high-dose post-transplant cyclophosphamide (PTCy) haploidentical has proven feasible and effective overcoming negative impact HLA disparity on survival. We hypothesized that PTCy could also be MMUD transplantation. retrospectively analyzed 86 consecutive adult recipients alloHSCT our...
Persistent thrombocytopenia is a common complication after allogeneic hematopoietic stem cell transplantation (allo-SCT). Romiplostim and eltrombopag are the currently available thrombopoietin receptor agonists (TPO-RAs), some studies with very small numbers of cases have reported their potential efficacy in allo-SCT setting. The present retrospective study evaluated safety TPO-RAs 86 patients persistent allo-HSCT. Sixteen (19%) had isolated (PT), 71 (82%) secondary failure platelet recovery...
We aimed to describe the epidemiology, risk factors, and clinical outcomes of co-infections superinfections in onco-hematological patients with COVID-19.International, multicentre cohort study cancer COVID-19. All were included analysis at diagnosis, while only admitted least 48 h superinfections.684 (384 solid tumors 300 hematological malignancies). Co-infections documented 7.8% (54/684) 19.1% (113/590) patients, respectively. Lower respiratory tract infections most frequent infectious...
This study investigates early cardiac events (ECEs) occurring during the first 180 days after allogeneic hematopoietic cell transplant (allo-HCT) in 416 adults receiving posttransplant cyclophosphamide (PTCY) (n = 258) or not PTCY 158). Total body irradiation (TBI) was given to 133 (31.9%) patients, of whom 111 (83.4%) received TBI combined with PTCY. The day +180 cumulative incidence function (CIF) ECEs 8.4%, heart failure 13) and pericardial complications 11) being most prevalent...
Tacrolimus (Tac) is pivotal in preventing acute graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (alloHSCT). It has been reported that genetic factors, including
PTCY 50 mg/kg/day on days +3/+4 is an excellent strategy to prevent GVHD. However, its use associated with adverse outcomes such as delayed engraftment, increased risk of infection, and cardiac complications. This pilot study evaluates the efficacy toxicity a reduced dose (40 mg/kg/day) combined tacrolimus in 22 peripheral blood HLA-matched alloHSCT patients. At day +100, cumulative incidences grade II–IV III–IV acute GVHD were 18.2% 4.5%, respectively. No IV or steroid-refractory disease...
Chronic graft-vs-host disease (cGvHD) is a severe immune-mediated complication that affects patients following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Oral manifestations of cGvHD, such as ulcers and mucosal inflammation, significantly impair quality life often require long-term treatment. Existing therapies provide limited relief, prompting the exploration new approaches, including use autologous platelet lysate (PL) gel for its regenerative properties. This...
Background/Objectives: This study evaluated infectious complications and immune reconstitution in 253 adults undergoing peripheral blood allogeneic hematopoietic cell transplantation (allo-HCT) with post-transplant cyclophosphamide (PTCY)-based GVHD prophylaxis. Methods: Patients received grafts from HLA-matched donors (47.4%), mismatched unrelated (MMUD, 33.2%), or haploidentical (19.4%). Results: The estimated 2-year non-relapse mortality (NRM) was 11.8%, 26.4%, 22.4%, respectively (p =...
Purpose One of the most significant limitations at-home autologous stem-cell transplantation (ASCT) is necessity for hospital readmission. We developed an ASCT program in which prophylactic ceftriaxone and treatment febrile neutropenia with piperacillin tazobactam was introduced to minimize readmission rate. Patients Methods Between November 2000 February 2005, 178 consecutive patients underwent a hematologic malignancy. Of these, 50 fulfilled requirements ASCT. Results were compared those...
This study was conducted to determine whether the integration of Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) and European Group for Blood Marrow (EBMT) score would improve individual capacity stratification high-risk HCT candidates. A total 442 consecutive patients receiving an allogeneic after reduced-toxicity conditioning included. Final HCT-CI EBMT scores were calculated validated. Then, grouped into a 6-category new combination model according (0, 1 2, ≥ 3) (0 3, 4 7),...
Strategies for reversing graft failure (GF) after allogeneic stem cell transplant (SCT) depend on the options available in each situation. GF was reported 16 Spanish institutions from January 2006 to July 2011. Primary defined as an absolute neutrophil count (ANC) > 0.5 × 109/L not reached by day + 28 SCT peripheral blood (PB) or bone marrow (BM) progenitors and 42 unrelated cord (UCB) progenitors. Secondary a recurrent ANC < 109/L. Eighty-nine patients with were reported, 80 received second...